Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic spontaneous urticaria
Biotech
Incyte's $750M buyout rocked by pause on key trial, asset cull
Less than six months after closing the deal, Incyte has paused a key study over preclinical toxicology findings and axed another program altogether.
Nick Paul Taylor
Nov 19, 2024 4:12am
Jasper dials up dose after hives responses come and go quickly
Oct 14, 2024 9:43am
Celldex anti-cKIT antibody reduces hives in another phase 2 test
Jul 30, 2024 5:50am
Novartis lines up another potential indication for BTK inhibitor
Mar 9, 2024 12:00pm
Sanofi BTK inhibitor readout in chronic hives sets up ph. 3 push
Feb 26, 2024 10:35am
Jasper eyes next indication for hive drug, thanks to mouse data
Feb 26, 2024 6:00am
